Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

Omitting sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer undergoing breast-conserving surgery may not increase the risk for recurrence over 5 years, according to findings ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Fig 1. Summary of key recommendations. ALN, axillary lymph node; ALND, axillary lymph node dissection; CDK, cyclin-dependent kinase; cm, centimeter; H, high; HER2 ...

The findings add to a growing body of evidence that treatment de-escalation is feasible and safe for favorable-risk early ...

Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...

Adoption of recommendations to skip sentinel lymph node biopsy (SLNB) in older women with hormone-receptor (HR)-positive, HER2-negative early-stage breast cancer may be slowly gaining traction in the ...

Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...

Your breast cancer stage plays an important role in your treatment choices. For stages II and III, treatment often involves some combination of chemotherapy, radiation therapy, surgery, targeted drugs ...